Literature DB >> 19584306

Functional selectivity of natural and synthetic prostaglandin EP4 receptor ligands.

Martin Leduc1, Billy Breton, Céline Galés, Christian Le Gouill, Michel Bouvier, Sylvain Chemtob, Nikolaus Heveker.   

Abstract

Classically, the prostaglandin E(2) (PGE(2)) receptor EP(4) has been classified as coupling to the Galpha(s) subunit, leading to intracellular cAMP increases. However, EP(4) signaling has been revealed to be more complex and also involves coupling to pertussis toxin-sensitive Galpha(i) proteins and beta-arrestin-mediated effects. There are now many examples of selective activation of independent pathways by G protein-coupled receptor (GPCR) ligands, a concept referred to as functional selectivity. Because most EP(4) ligands had thus far only been functionally characterized by their ability to stimulate cAMP production, we systematically determined the potencies and efficacies of a panel of EP(4) ligands for activation of Galpha(s), Galpha(i), and beta-arrestin relative to the endogenous ligand PGE(2). For this purpose, we adapted three bioluminescence resonance energy transfer (BRET) assays to evaluate the respective pathways in living cells. Our results suggest considerable functional selectivity among the tested, structurally related agonists. PGE(2) was the most selective in activating Galpha(s), whereas PGF(2alpha) and PGE(1) alcohol were the most biased for activating Galpha(i1) and beta-arrestin, respectively. We observed reversal in order of potencies between beta-arrestin 2 and Galpha(i1) functional assays comparing PGE(1) alcohol and either PGF(2alpha), PGD(2), or 7-[(1R,2R)-2-[(E,3R)-3-hydroxy-4-(phenoxy)but-1-enyl]-5-oxocyclopentyl]heptanoic acid (M&B28767). Most ligands were full agonists for the three pathways tested. Our results have implications for the use of PGE(2) analogs in experimental and possibly clinical settings, because their activity spectra on EP(4) differ from that of the native agonist. The BRET-based methodology used for this first systematic assessment of a set of EP(4) agonists should be applicable for the study of other GPCRs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19584306     DOI: 10.1124/jpet.109.156398

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  39 in total

Review 1.  Probing heterotrimeric G protein activation: applications to biased ligands.

Authors:  Colette Denis; Aude Saulière; Segolene Galandrin; Jean-Michel Sénard; Céline Galés
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

2.  Functional selective oxytocin-derived agonists discriminate between individual G protein family subtypes.

Authors:  Marta Busnelli; Aude Saulière; Maurice Manning; Michel Bouvier; Celine Galés; Bice Chini
Journal:  J Biol Chem       Date:  2011-11-08       Impact factor: 5.157

3.  Endocytic profiles of δ-opioid receptor ligands determine the duration of rapid but not sustained cAMP responses.

Authors:  Hanieh Bagheri Tudashki; Derek N Robertson; Peter W Schiller; Graciela Pineyro
Journal:  Mol Pharmacol       Date:  2013-10-30       Impact factor: 4.436

4.  High-Affinity Binding of Chemokine Analogs that Display Ligand Bias at the HIV-1 Coreceptor CCR5.

Authors:  Carlos A Rico; Yamina A Berchiche; Mizuho Horioka; Jennifer C Peeler; Emily Lorenzen; He Tian; Manija A Kazmi; Alexandre Fürstenberg; Hubert Gaertner; Oliver Hartley; Thomas P Sakmar; Thomas Huber
Journal:  Biophys J       Date:  2019-08-02       Impact factor: 4.033

Review 5.  The year in G protein-coupled receptor research.

Authors:  Robert P Millar; Claire L Newton
Journal:  Mol Endocrinol       Date:  2009-12-17

Review 6.  Are circulating gonadotropin isoforms naturally occurring biased agonists? Basic and therapeutic implications.

Authors:  Brian J Arey; Francisco J López
Journal:  Rev Endocr Metab Disord       Date:  2011-12       Impact factor: 6.514

7.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

8.  Different contributions of chemokine N-terminal features attest to a different ligand binding mode and a bias towards activation of ACKR3/CXCR7 compared with CXCR4 and CXCR3.

Authors:  Martyna Szpakowska; Amanda M Nevins; Max Meyrath; David Rhainds; Thomas D'huys; François Guité-Vinet; Nadine Dupuis; Pierre-Arnaud Gauthier; Manuel Counson; Andrew Kleist; Geneviève St-Onge; Julien Hanson; Dominique Schols; Brian F Volkman; Nikolaus Heveker; Andy Chevigné
Journal:  Br J Pharmacol       Date:  2018-03-23       Impact factor: 8.739

9.  The EP1/EP3 receptor agonist 17-pt-PGE2 acts as an EP4 receptor agonist on endothelial barrier function and in a model of LPS-induced pulmonary inflammation.

Authors:  Anna Theiler; Viktoria Konya; Lisa Pasterk; Jovana Maric; Thomas Bärnthaler; Ilse Lanz; Wolfgang Platzer; Rufina Schuligoi; Akos Heinemann
Journal:  Vascul Pharmacol       Date:  2016-09-21       Impact factor: 5.773

10.  Restoration of renal function by a novel prostaglandin EP4 receptor-derived peptide in models of acute renal failure.

Authors:  Martin Leduc; Xin Hou; David Hamel; Melanie Sanchez; Christiane Quiniou; Jean-Claude Honoré; Olivier Roy; Ankush Madaan; William Lubell; Daya R Varma; Joseph Mancini; François Duhamel; Krishna G Peri; Vincent Pichette; Nikolaus Heveker; Sylvain Chemtob
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-11-14       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.